Table 1 Rates of de novo and salvage produced dCTP incorporation into newly replicated DNA

From: ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways

Treatment

De novoa

Salvagea

Ratio (salvage/de novo)

Not treated

0.20 ± 0.01

0.17 ± 0.01

0.83

VE-822

0.17 ± 0.01

0.14 ± 0.01

0.85

dCKi

0.23 ± 0.01

0.019 ± 0.004

0.082

VE-822 + dCKi

0.19 ± 0.01

0.022 ± 0.002

0.12

  1. aSlope ± standard error of regression line in arbitrary unit